ASMB ASMB
Company Profile ↓Company Overview
ASMB (ASMB) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $72.30M (+153.5% YoY); net profit $-6.12M.
- Trailing 12 Months Year-on-year growth — revenue +153.5%.
- 5-Year Trend Long-term compounding — revenue CAGR -1.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -1.78% |
| 1 Year: | 153.52% |
Stock Price Performance
| 1 Year: | +36.78% |
| 6 Months: | -6.04% |
| 3 Months: | -10.20% |
| 1 Month: | -8.41% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)52.56 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -1.8% CAGR over 5 years.
- Trading 31.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 2.36M | 2.66M | - | 3.56M | 3.22M | 4.29M | - | 3.88M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -7.20M | -7.15M | -7.12M | - | -11.28M | -10.45M | -11.68M | - | -13.93M | -13.57M | -12.45M | - | -16.67M | -27.17M | -22.57M | - | -28.34M | -19.70M | -25.99M | - | -27.69M | 6.58M | -4.02M | - | -27.26M | -23.67M | -18.88M | -23.16M | -24.57M | -23.40M | -19.56M | -17.49M | -15.05M | -10.73M | -12.20M | -10.96M | -9.94M | -11.09M | -10.88M | -11.37M |
| Net Income | -7.14M | -6.94M | -6.62M | -7.75M | -10.99M | -10.15M | -11.57M | -11.55M | -13.93M | -13.60M | -12.27M | -3.01M | -16.25M | -26.81M | -21.54M | -26.16M | -27.05M | -18.50M | -25.00M | -27.08M | -26.66M | 7.27M | -3.35M | -39.42M | -27.20M | -23.59M | -18.80M | -23.09M | -24.46M | -23.14M | -18.95M | -16.90M | -14.42M | -9.08M | -11.15M | -9.61M | -8.82M | -10.20M | -9.20M | -9.08M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.80 | -1.30 | -0.87 | - | -1.05 | -0.72 | -0.96 | - | -0.76 | 0.19 | -0.09 | -1.11 | - | -0.55 | -0.41 | -0.48 | -0.51 | -0.48 | -4.46 | -3.88 | -3.29 | -1.66 | -1.98 | -1.51 | -1.17 | -1.33 | -0.72 | -0.54 |
| R&D Expense | 3.83M | 4.67M | 4.63M | - | 8.12M | 7.52M | 8.83M | - | 10.57M | 12.13M | 10.93M | - | 14.54M | 17.84M | 19.11M | - | 22.70M | 18.70M | 21.74M | - | 23.05M | 23.33M | 26.94M | - | 18.55M | 16.75M | 18.47M | 17.20M | 17.79M | 18.13M | 14.55M | 12.52M | 10.82M | 11.88M | 16.26M | 13.52M | 14.85M | 16.12M | 16.59M | 14.90M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 9.02M | 14.80M | 15.96M | 79.11M | 6.25M | 0 | 7.16M | 28.52M | 72.30M |
| Operating Income | - | - | -3.34M | -4.77M | -34.00M | -24.86M | -19.60M | -23.96M | -29.66M | -45.28M | -52.23M | -92.73M | -102.71M | -64.78M | -132.69M | -94.11M | -64.65M | -45.42M | -12.12M |
| Net Income | -4.57M | -8.79M | -4.54M | -15.29M | -34.34M | -24.79M | -19.40M | -23.79M | -28.45M | -44.26M | -42.81M | -90.75M | -97.63M | -62.15M | -129.85M | -93.09M | -61.23M | -40.18M | -6.12M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.00 | -23.08 | -13.38 | -6.69 | -0.55 |
| R&D Expense | - | - | 2.94M | 1.85M | 25.28M | 19.51M | 15.03M | 10.72M | 18.36M | 33.09M | 44.23M | 72.74M | 85.76M | 106.82M | 68.52M | 69.98M | 48.90M | 55.93M | 64.81M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2005 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | 14.62M | 37.05M | 20.56M | 27.13M | 71.23M | 133.74M | 98.12M | 169.30M | 268.05M | 339.91M | 283.25M | 191.06M | 101.79M | 136.82M | 119.17M | 257.59M |
| Total Equity | - | -4.38M | -9.46M | -13.36M | 11.63M | 34.53M | 17.81M | 24.49M | 58.57M | 118.74M | 79.88M | 113.12M | 210.65M | 273.22M | 240.58M | 168.93M | 82.66M | 41.10M | 33.36M | 206.75M |
| Cash & Equivalents | 0 | - | 15.85K | 81.29K | 14.57M | 36.98M | 20.49M | 27.06M | 29.09M | 27.11M | 28.57M | 82.03M | 41.47M | 46.73M | 59.44M | 45.63M | 52.42M | 19.84M | 38.34M | 58.45M |
| Total Liabilities | - | - | - | - | 2.99M | 2.51M | 2.75M | 2.64M | 12.65M | 15.00M | 18.24M | 56.18M | 57.39M | 66.69M | 42.68M | 22.13M | 19.13M | 95.73M | 85.81M | 50.84M |
| Current Liabilities | - | - | - | - | 1.72M | 2.51M | - | 2.64M | 1.05M | 3.40M | 7.12M | 13.49M | 18.47M | 24.44M | 24.43M | 16.07M | 16.30M | 39.23M | 47.80M | 48.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.48M | -5.21M | -25.07M | -21.38M | -17.80M | -14.97M | -18.70M | -34.88M | 1.86M | -64.96M | -84.07M | -62.96M | -93.40M | -84.46M | 22.74M | -51.12M | -41.09M |
| Investing Cash Flow | - | - | -11.96K | -3.24K | -6.48K | 277.40K | -64.86M | 36.20M | -15.64M | -135.40M | -50.32M | 68.07M | 26.52M | 90.64M | -69.14M | 40.17M | -113.47M |
| Financing Cash Flow | 3.55M | 19.70M | 47.49M | 4.90M | 24.37M | 16.73M | 81.57M | 153.00K | 67.24M | 159.79M | 139.65M | 7.60M | 53.06M | 614.00K | 13.82M | 29.45M | 174.67M |
| Capital Expenditure | -2.57K | -0 | -11.96K | -3.24K | -6.48K | -149.96K | -58.26K | -147.00K | -865.00K | -340.00K | -1.55M | -470.00K | -3.10M | -102.00K | -255.00K | -28.00K | -66.00K |
| Free Cash Flow | -3.49M | -5.21M | -25.08M | -21.38M | -17.80M | -15.12M | -18.76M | -35.03M | 995.00K | -65.30M | -85.62M | -63.43M | -96.49M | -84.56M | 22.49M | -51.15M | -41.16M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | -579.1% | -626.4% | -643.4% | -81.9% | -2,121.7% | - | -902.5% | -159.3% | -16.8% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | -474.7% | -613.0% | -611.6% | -78.6% | -2,076.4% | - | -854.8% | -140.9% | -8.5% |
| ROE % | 104.2% | 92.9% | 34.0% | -131.5% | -99.5% | -139.2% | -79.2% | -40.6% | -24.0% | -55.4% | -37.8% | -43.1% | -35.7% | -25.8% | -76.9% | -112.6% | -149.0% | -120.4% | -3.0% |
| ROCE % | - | - | - | -37.0% | -98.5% | - | -80.0% | -34.1% | -22.8% | -49.8% | -33.5% | -37.2% | -32.6% | -25.0% | -75.8% | -110.1% | -66.2% | -63.6% | -5.8% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ASMB
Understanding Momentum Shifts in (ASMB) - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNTGdSdGtNN0tPcHlDS3pVNzhIdFhQNC13WGo2aVQ2RHJscWpmZGlobHZkTEVTTE1oWUkyYlZpZTNEblgyVEdfVVhMWXlzMV9hV19LZDlXR0VRbExQQWVTcHJ1WU9yTU5vWk5FU3lUSS16WjhlWnRuSmVoeFZ6bkt1NWFqeUxNbXV5dW1iSl…
We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxNaVp1dVdTNHdJUzFSdnozTC1HUDFEMW80eG9DMWRqbFJmWlVzakwybU5FQzBMdFZNQ2UwSTJyYXdsRmVwM1RXcWtObkJ3XzFOMVhrWTVraHloMEJmNUNfeGJ2eE56QmtGR1l4RU9sSk5TM0NCNlNCTFZHZV9IR0gtZDY3eUdHc2ZTanZ5ak…
Assembly Biosciences: A Gilead-Backed Antiviral Option With Underrated Leverage (ASMB) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxORTVMaGp1NnVUSHFrV2w2WmM0aElnMlJZUm9JS0hSWXBpcUN6cThveEhsQXBubDBLUWM3NkoyclV3T0xDcllQYTJ3ZDdtaVVQYWhoSHBuRkhXM1BwY2NiZ2hkMUlQVXdvYmRYVW1ld0M5Znp4ZFItNjQxMU9wYTNIU0JjWXRWcWFFVDNIOF…
ASMB Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9zYW9lc0k2aUVUVzJIUEt4NTFGdW9Wb0JjdWxJVGROeUpnbWs2dnItWW9DbGFwT01zWWFaMy1Kb2dUWFYyaWxyLVpNV3gzdUVJbDRYOEJTWWNuUHFrXzNTeUw1YjctU0R2NUc0VTR3WGZvVmJrTUMwWnZB?oc=5" target="_blank">ASM…
ASMB|Assembly Biosciences Inc|Price:25.510|Chg%:+0.400 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFBwSEVlQWctbXN6RlZ3dGZNSWthQUNqWF9uaWVtY24yVjRFQVpsT1hCaUxpbjhHRC1JcFkzaHVBb2Q0R1R5Y1NzTlBfM2dEbHd5cnR3YWJfWjJTM0FCMDJReTdydXpiRGlYbjRDcV93?oc=5" target="_blank">ASMB|Assembly Biosc…
These Analysts Just Made A Huge Downgrade To Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Forecasts - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxQb3JlSHVoSGZQeUhTRzBuenVZME10N0RsUHd1a00wcjFPcmhSRjZQS29tdkt0cGFoalN3TzRSTk1IUlBydkNiOV83b0lIM292NmlBeDJ6bVF4Mk1LT0NsTUJBNWpkZ0s2QnB0U3l0U3RkTlRwZ3NnQmZEd0NrQTg4LWZKVGpsOUxFY1RlVm…
ASMB — Frequently Asked Questions
What is the current share price of ASMB?
As of 2026-08-05 17:25 PDT, ASMB trades at $26.54 on NASDAQ/NYSE. Its 52-week range is $18.86 to $38.50.
What is the P/E ratio of ASMB?
ASMB trades at a trailing price-to-earnings (P/E) ratio of -48.25.
What is the return on equity (ROE) of ASMB?
ASMB has a return on equity (ROE) of -2.96%. Its return on capital employed (ROCE) is -5.80%.
Is ASMB a good stock to buy?
This page provides a data-driven analysis of ASMB, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.